Cracow

• A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma C … Recruiting
  2024-515273-10-00 7 2021-10-19 Relapsed or refractory Multiple Myeloma (r/r MM)
• A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC) Recruiting
  2023-505163-37-00 3 2021-10-01 Metastatic Colorectal Cancer
• A Study to Learn About the Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Children and Adolescents. Recruiting
  2024-512743-23-00 5 2021-08-31 Acute Migraine (with or without aura)
• A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting
  2023-507202-14-00 7 2021-04-29 Upper limb spasticity after stroke or traumatic brain injury
• A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies Recruiting
  2023-504931-42-00 4 2021-04-06 Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters tran
• Apremilast Study in Children with Active Juvenile Psoriatic Arthritis Recruiting
  2023-503435-17-00 5 2021-03-31 Juvenile psoriatic arthritis
• Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negativ … Recruiting
  2024-515063-66-00 4 2021-03-30 Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli … Recruiting
  2024-512671-12-00 10 2021-03-05 Unresectable head and neck squamous cell carcinoma, metastatic head an
• PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES Recruiting
  2024-518454-17-00 1 2021-01-08 relapsed/refractory hematologic malignancies
• An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the i … Recruiting
  2023-504417-67-00 6 2020-12-22 Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Sp
• A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects wi … Recruiting
  2024-514010-12-00 1 2020-12-03 Advanced Malignancies
• A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting
  2023-504888-16-00 9 2020-10-05 Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressi
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with chronic inflammatory demyel … Recruiting
  2023-507885-21-00 4 2020-08-18 Chronic Inflammatory Demyelinating Polyneuropathy
• Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting
  2023-509179-18-00 1 2019-08-13 Castration Resistant Prostate Cancer (CRPC)
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Paediatric Hepatic International Tumour Trial Recruiting
  2024-516110-38-00 5 2018-03-06 Hepatoblastoma and Hepatocellular Carcinoma
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended recruitment
  2025-521067-13-00 5 2026-04-24 Atherosclerotic Cardiovascular Disease (ASCVD)
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended recruitment
  2025-521918-26-00 4 2026-02-11 HIV Infections
• A Study Evaluating BFB759 in Atopic Dermatitis Ended recruitment
  2025-521624-30-00 4 2026-01-08 Atopic dermatitis
• A study to find if tibulizumab works and how safe it is in participants with systemic sclerosis Ended recruitment
  2024-519335-42-01 4 2025-12-22 Systemic Sclerosis
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038) Ended recruitment
  2025-521970-33-00 5 2025-12-19 ​​Pulmonary Arterial Hypertension (PAH)
• SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease Ended recruitment
  2025-521791-63-00 4 2025-12-18 Moderately to Severely Active Rheumatologic Disease

Showing 457–480 of 1,081 trials